AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Ovid Therapeutics Inc.
Video analysis: OVID
All videosNo video analysis for this stock yet. Request one from our team.
News: OVID
Ovid Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company's management will participate in two upcoming investor conferences: Cantor Global Healthcare Conference – Wednesday, September 9 at 2:10 pm ET H.C.
BlackRock Inc. Takes Position in Ovid Therapeutics $OVID
BlackRock Inc. bought a new position in shares of Ovid Therapeutics (NASDAQ: OVID) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 10,823,480 shares of the company's stock, valued at approximately $29,115,000. BlackRock Inc. owned 5.80% of Ovid Therapeutics
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.06 per share a year ago.
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the second quarter ended June 30, 2026.
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ally Bridge Group NY LLC Has $6.26 Million Position in Ovid Therapeutics $OVID
Ally Bridge Group NY LLC raised its stake in Ovid Therapeutics (NASDAQ: OVID) by 57.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,818,459 shares of the company's stock after buying an additional 1,033,459 shares during the quarter. Ovid Therapeutics
ADAR1 Capital Management LLC Acquires 259,113 Shares of Ovid Therapeutics $OVID
ADAR1 Capital Management LLC grew its holdings in Ovid Therapeutics (NASDAQ: OVID) by 6.0% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,544,113 shares of the company's stock after acquiring an additional 259,113 shares during the quarter. ADAR1 Capital Management LLC owned
